SEC Comment Letter 0000000000-24-006950 to CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc.
Date: June 17, 2024 · CIK: 0001343009 · Accession: 0000000000-24-006950
AI Filing Summary & Sentiment
File numbers found in text: 000-52403
Letter
United States securities and exchange commission logo June 17, 2024 Eyal Barad Chief Executive Officer CNBX Pharmaceuticals Inc. #3 Bethesda Metro Center, Suite 700 Bethesda, MD 20814 Re:CNBX Pharmaceuticals Inc. Form 10-K for the Fiscal Year Ended August 31, 2023 Filed November 30, 2023 File No. 000-52403 Dear Eyal Barad: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 17, 2024
Eyal Barad
Chief Executive Officer
CNBX Pharmaceuticals Inc.
#3 Bethesda Metro Center, Suite 700
Bethesda, MD 20814
Re:CNBX Pharmaceuticals Inc.
Form 10-K for the Fiscal Year Ended August 31, 2023
Filed November 30, 2023
File No. 000-52403
Dear Eyal Barad:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences